Compass Therapeutics (CMPX) to Release Quarterly Earnings on Monday

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) is projected to release its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect Compass Therapeutics to post earnings of ($0.12) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by ($0.01). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Price Performance

Shares of NASDAQ CMPX opened at $1.89 on Monday. The company has a 50-day simple moving average of $2.10 and a 200-day simple moving average of $2.10. The company has a market cap of $261.35 million, a PE ratio of -5.11 and a beta of 1.40. Compass Therapeutics has a 12 month low of $0.77 and a 12 month high of $4.08.

Wall Street Analysts Forecast Growth

Several analysts have commented on CMPX shares. Jefferies Financial Group lifted their target price on shares of Compass Therapeutics from $7.00 to $8.00 and gave the stock a "buy" rating in a research note on Monday, February 10th. D. Boral Capital reiterated a "buy" rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Monday, April 28th. Guggenheim reissued a "buy" rating on shares of Compass Therapeutics in a research note on Tuesday, April 22nd. Wedbush reaffirmed an "outperform" rating and set a $8.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, April 1st. Finally, Leerink Partnrs upgraded shares of Compass Therapeutics from a "hold" rating to a "strong-buy" rating in a report on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $13.38.

Insider Transactions at Compass Therapeutics

In other Compass Therapeutics news, insider Jonathan Anderman acquired 20,000 shares of the firm's stock in a transaction on Monday, April 7th. The stock was bought at an average cost of $1.54 per share, for a total transaction of $30,800.00. Following the completion of the purchase, the insider now directly owns 21,000 shares in the company, valued at $32,340. This represents a 2,000.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. Company insiders own 28.50% of the company's stock.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.